Literature DB >> 21281710

No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls.

Sarven Sabunciyan1, Nataniel Mandelberg, Charles S Rabkin, Robert Yolken, Raphael Viscidi.   

Abstract

New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21281710      PMCID： PMC3285460          DOI： 10.1016/j.mcp.2011.01.005

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN： 0890-8508            Impact factor:   2.365


  7 in total

1.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.

Authors:  Graham Casey; Phillippa J Neville; Sarah J Plummer; Ying Xiang; Lisa M Krumroy; Eric A Klein; William J Catalona; Nina Nupponen; John D Carpten; Jeffrey M Trent; Robert H Silverman; John S Witte
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

2.  XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH.

Authors:  Rebecca S Arnold; Natalia V Makarova; Adeboye O Osunkoya; Suganthi Suppiah; Takara A Scott; Nicole A Johnson; Sushma M Bhosle; Dennis Liotta; Eric Hunter; Fray F Marshall; Hinh Ly; Ross J Molinaro; Jerry L Blackwell; John A Petros
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

3.  Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum.

Authors:  E P DiMagno; D Corle; J F O'Brien; I J Masnyk; V L Go; R Aamodt
Journal:  Mayo Clin Proc       Date:  1989-10       Impact factor: 7.616

4.  An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

Authors:  Beihua Dong; Sanggu Kim; Seunghee Hong; Jaydip Das Gupta; Krishnamurthy Malathi; Eric A Klein; Don Ganem; Joseph L Derisi; Samson A Chow; Robert H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-18       Impact factor: 11.205

5.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Authors:  Robert Schlaberg; Daniel J Choe; Kristy R Brown; Harshwardhan M Thaker; Ila R Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-08       Impact factor: 11.205

6.  Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

Authors:  Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi
Journal:  PLoS Pathog       Date:  2006-03-31       Impact factor: 6.823

7.  Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.

Authors:  Oliver Hohn; Hans Krause; Pia Barbarotto; Lars Niederstadt; Nadine Beimforde; Joachim Denner; Kurt Miller; Reinhard Kurth; Norbert Bannert
Journal:  Retrovirology       Date:  2009-10-16       Impact factor: 4.602
  7 in total
  7 in total

Review 1.  Recombinant origin, contamination, and de-discovery of XMRV.

Authors:  Krista Delviks-Frankenberry; Oya Cingöz; John M Coffin; Vinay K Pathak
Journal:  Curr Opin Virol       Date:  2012-07-19       Impact factor: 7.090

2.  Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection.

Authors:  Marta Curriu; Jorge Carrillo; Marta Massanella; Elisabet Garcia; Francesc Cunyat; Ruth Peña; Peter Wienberg; Cristina Carrato; Joan Areal; Margarita Bofill; Bonaventura Clotet; Julià Blanco; Cecilia Cabrera
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.752

3.  Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer.

Authors:  Jonas Blomberg; Ali Sheikholvaezin; Amal Elfaitouri; Fredrik Blomberg; Anna Sjösten; Johan Mattson Ulfstedt; Rüdiger Pipkorn; Clas Källander; Christina Ohrmalm; Göran Sperber
Journal:  Adv Virol       Date:  2011-09-04

4.  Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

Authors:  Tanyaradzwa P Ndongwe; Adeyemi O Adedeji; Eleftherios Michailidis; Yee Tsuey Ong; Atsuko Hachiya; Bruno Marchand; Emily M Ryan; Devendra K Rai; Karen A Kirby; Angela S Whatley; Donald H Burke; Marc Johnson; Shilei Ding; Yi-Min Zheng; Shan-Lu Liu; Ei-Ichi Kodama; Krista A Delviks-Frankenberry; Vinay K Pathak; Hiroaki Mitsuya; Michael A Parniak; Kamalendra Singh; Stefan G Sarafianos
Journal:  Nucleic Acids Res       Date:  2011-09-08       Impact factor: 16.971

5.  No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population.

Authors:  Mark James Robinson; Philip William Tuke; Otto Erlwein; Kate I Tettmar; Steve Kaye; Kikkeri N Naresh; Anup Patel; Marjorie M Walker; Takahiro Kimura; Ganesh Gopalakrishnan; Richard S Tedder; Myra O McClure
Journal:  Adv Virol       Date:  2011-06-09

6.  Testing strategies for detection of xenotropic murine leukemia virus-related virus infection.

Authors:  Shixing Tang; Indira K Hewlett
Journal:  Adv Virol       Date:  2011-07-28

7.  Downregulation of APOBEC3G by xenotropic murine leukemia-virus related virus (XMRV) in prostate cancer cells.

Authors:  Abhinav Dey; Chinmay Kumar Mantri; Jui Pandhare-Dash; Bindong Liu; Siddharth Pratap; Chandravanu Dash
Journal:  Virol J       Date:  2011-12-12       Impact factor: 4.099
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.